Please complete at least one question.
Prof Peter Schmid - Barts Cancer Institute, London, UK
Prof Schmid presents research from a phase Ia expansion study at AACR 2017, evaluating responses to atezolizumab in patients with metastatic triple negative breast cancer.
Slides from this presentation are available here.
Prof Schmid discussed these results further with ecancer here.